Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Patent
1994-03-10
1995-08-08
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
435226, 435 691, 4352402, 4353201, 536 232, 424 9463, C12N 948, C12N 1558, A61K 37547
Patent
active
054396794
ABSTRACT:
Novel polypeptide compositions based on the amino acid sequence of tissue plasminogen activator (tPA) are provided having improved properties over natural tissue plasminogen activator. Particularly, enhanced specific activity, reduced response to inhibition by plasminogen activator inhibitor, fibrin stimulation of plasminogenolytic activity and/or enhanced affinity to fibrin surfaces are provided by modifying one or more loci by deletions or substitutions. One or both of the N- or C-termini may be modified.
The plasmids designated 1, 2 and 3 were deposited at the A.T.C.C. on Dec. 20, 1985 and given A.T.C.C. designations 40214, 40215 and 40216, respectively.
REFERENCES:
patent: 4751084 (1988-06-01), Feder et al.
patent: 4753879 (1988-06-01), Rosa et al.
patent: 5073494 (1991-12-01), Heyneker et al.
patent: 5106741 (1992-04-01), Marotti et al.
patent: 5147643 (1992-09-01), Heyneker et al.
patent: 5344773 (1994-09-01), Wei et al.
Pohl, G. et al, Biochemistry, vol. 23, pp. 3701-3707, 1984.
Zoller, M. et al, Nuc. Acids Res, vol. 10, pp. 6487-6500, 1982.
Opdenakker, G. et al, Embo Workshop on Plasminogen Activators, Amalfi, Italy, Oct. 14-18, 1985.
Haigwood, Nancy L. et al., "Variants of Human Tissue--Type Plasminogen Activator Substituted at the Protein Cleavage Site and Glycosylation Sites, and Truncated at the N--and C--termini," Protein Engineering, vol. 2, No. 8, pp. 611-620 (1989).
Craik, Charles S. et al., "Redesigning Trypsin: Altera--of Substrate Specificity," Science, vol. 228, pp. 291-297 (Apr. 1985).
Rosenberg, Steven et al., "Synthesis in yeast of a functional oxidation--resistant mutant of human .alpha..sub.1 --antitrypsin," Nature, vol. 312, No. 5989, pp. 77-80 (Nov. 1984).
Wilkinson, Anthony J. et al., "A large increase in enzyme--substrate affinity by protein engineering," Nature, vol. 307, pp. 187-188 (Jan. 1984).
Andreasen, P. A., "Inactive proenzyme to tissue--type plasminogen activator from human melanoma cells, identified after affinity purification with a mono--clonal antibody," Embo Journal, vol. 3, pp. 51-55 (1984).
Ny et al., Figure I, Proc. Natl. Acad. Sci. USA, vol. 81, p. 5355 (1984).
van Zonneveld, A. J., Abstract from ISTH Meeting, Jul. 14-19, 1985, report on the relationship between structure and function of human tissue--type plasminogen activator.
Loskutoff, D. J. et al., "Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells," Proc. Natl. Acad. Sci. USA, vol. 80, pp. 2956-2960 (May 1963).
Loskutoff, D. J. "Thrombosis and Haemostasis," Journal of the International Society of Thrombosis and Haemostasis, vol. 54, No. 1, p. 118 (S699).
Zoller, Mark J. et al., "Oligonucleotide--Directed Mutagenesis of DNA Fragments Cloned into M13 Vectors," Methods in Enzymology, vol. 100, pp. 468-500 (1983).
Guan, Jun--Lin et al., "Glycosylation Allows Cells--Surface Transport of an Anchored Secretory Protein," Cell, vol. 42, pp. 489-496 (Sep. 1965).
Little, Sheila P. et al., "Functional Properties of Carbohydrate--Depleted Tissue Plasminogen Activator," Biochemistry, vol. 23, pp. 6191-6195 (1984).
Nose, Masato et al., "Biological significance of carbohydrate chains on monoclonal antibodies," Proc. Natl. Acad. Sci. USA, vol. 80, pp. 6632-6636 (Nov. 1983).
Vehar, Gordon A. et al., "Characterization Studies on Human Melanoma Cell Tissue Plasminogen Activator," Biotechnology, vol. 2, pp. 1051-1057 (1986).
Diane Pennica et al., "Cloning and Expression of Human Tissue--Type Plasminogen Activator cDNA in E. coli.", Nature, vol. 301, No. 5897, pp. 214-221 (1983).
Afting Ernest-Guenter
Haigwood Nancy L.
Mullenbach Guy
Paques Eric-Paul
Allen Marianne Porta
Behringwerke AG
Chiron Corporation
Draper Garnette D.
LandOfFree
Peptide plasminogen activators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide plasminogen activators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide plasminogen activators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-969694